IsoRay, Inc. (NYSEAMERICAN:ISR) shares gapped up prior to trading on Monday . The stock had previously closed at $0.50, but opened at $0.60. IsoRay shares last traded at $0.64, with a volume of 2,944,156 shares trading hands.

Separately, Zacks Investment Research lowered IsoRay from a “buy” rating to a “hold” rating in a research report on Wednesday, November 27th.

The stock has a 50-day simple moving average of $0.34 and a 200 day simple moving average of $0.39.

IsoRay (NYSEAMERICAN:ISR) last announced its quarterly earnings data on Tuesday, November 12th. The healthcare company reported ($0.01) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01. The firm had revenue of $2.32 million during the quarter, compared to the consensus estimate of $2.23 million.

In related news, CEO Lori A. Woods purchased 150,000 shares of IsoRay stock in a transaction dated Friday, November 15th. The shares were acquired at an average cost of $0.39 per share, for a total transaction of $58,500.00. Insiders acquired a total of 210,000 shares of company stock worth $81,900 over the last quarter.

A hedge fund recently raised its stake in IsoRay stock. Vanguard Group Inc. lifted its stake in IsoRay, Inc. (NYSEAMERICAN:ISR) by 11.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,594,907 shares of the healthcare company’s stock after purchasing an additional 169,100 shares during the period. Vanguard Group Inc. owned 2.37% of IsoRay worth $654,000 at the end of the most recent quarter.


IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Recommended Story: Why are analyst ratings important in trading stocks?

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.